Bicara Therapeutics BCAX

Claire Mazumdar, Ph.D. has served as our Chief Executive Officer and as a member of our board of directors since January 2020. Prior to Bicara, Dr. Mazumdar was Head of Business Development and Corporate Strategy at Rheos Medicines, Inc., a biopharmaceutical company, from August 2017 to December 2019, which culminated in a large multi-target discovery partnership with Roche. Previously, Dr. Mazumdar was an investment professional at Third Rock Ventures, LLC, or Third Rock, a life sciences venture capital firm, from July 2017 to July 2019. Dr. Mazumdar has served on the board of directors of Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, precision medicine company, since June 2025. Dr. Mazumdar received a B.S. in Biological Engineering from Massachusetts Institute of Technology, a Ph.D. in Cancer Biology from Stanford School of Medicine, and an M.B.A. from Stanford Graduate School of Business. Dr. Mazumdar is the niece of Kiran Mazumdar-Shaw, a member of our board of directors.

Ryan Cohlhepp, Pharm.D. has served as our President and Chief Operating Officer since October 2020, and as a member of our board of directors since August 2024 and previously from December 2020 to March 2023. Prior to Bicara, Dr. Cohlhepp was Senior Vice President, R&D Strategy and Operations at Rheos Medicines, Inc., a biopharmaceutical company, from March 2018 to October 2020. Earlier in his career, Dr. Cohlhepp served in roles of increasing responsibility at Takeda Oncology and Roche. Dr. Cohlhepp received a Pharm.D. from Purdue University.

David Raben, M.D. has served as our Chief Medical Officer since July 2023 and consulted for us from May 2023 to July 2023. Previously, Dr. Raben was Vice President of late-stage product development at Amgen Inc., a biotechnology company, from November 2021 to May 2023, where he led the FDA-approved tarlatamab program for extensive stage small cell lung cancer. From September 2019 to June 2021, he was Vice President of late-stage product development for lung, skin, head and neck cancer at Genentech, Inc., a biotechnology company. He also served as a Professor of Radiation Oncology at the University of Colorado Health from May 1998 to September 2019. Dr. Raben is a board-certified radiation oncologist with a career focused on investigating novel biologic strategies against growth factor signaling and immunosuppression for patients advanced lung and head and neck cancers. He earned a B.A. in Psychology from Duke University and an M.D. from the Bowman Gray School of Medicine at Wake Forest University, and completed his residency at the Johns Hopkins Hospital.

Michael Powell, Ph.D. has served as a member and as the Chairperson of our board of directors since August 2024. Since August 2025, Dr. Powell has served as a Venture Advisor at Lantana Ranch LLC. Dr. Powell was previously an Executive Partner/Venture Advisor at Omega Funds, a venture capital firm, from August 2021 until August 2025, and a General Partner at Sofinnova Investments, a biopharmaceutical investment firm, from August 1997 until June 2021. Dr. Powell served as a member of the board of directors of Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company, from November 2016 to December 2024, and the chair and a member of the board of directors of Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI), a biopharmaceutical company, from July 2015 to May 2022. Dr. Powell has also served on the boards of directors of several private companies. Dr. Powell received a B.S. in chemistry from Scarborough College, a Ph.D. in Physical Chemistry from the University of Toronto and completed post-doctoral studies in Bioorganic Chemistry at the University of California as a National Science and Engineering Research Council Scholar.

Scott Robertson has served as a member of our board of directors since September 2023. Mr. Robertson currently serves as the Chief Financial Officer and Chief Business Officer of Star Therapeutics, Inc., a biotechnology company, since January 2024. Mr. Robertson also served as the Chief Business and Financial Officer of DICE Therapeutics, Inc. (Nasdaq: DICE), a biotechnology company, from July 2021 to December 2023 (including following the company's acquisition by Eli Lilly and Company in August 2023), the Chief Financial Officer from December 2017 to July 2021, and as the Vice President, Business Development & Strategic Planning from April 2016 to December 2017. He previously served as a Lecturer at the Haas School of Business at the University of California, Berkeley and as a member of the board of directors of Hexima Limited (ASX: HXL), a biotechnology company, from December 2018 to September 2023. Mr. Robertson received his B.S. in Business Administration from the University of Southern California and his M.B.A. from the Haas School of Business at the University of California, Berkeley.

Nils Lonberg, Ph.D. has served as a member of our board of directors since April 2019 and was previously the Chairperson of our board of directors until August 2024. Since June 2025, Dr. Lonberg has served as Chief Executive Officer of Tripeaks Therapeutics, Inc., a biotechnology company. Dr. Lonberg also currently serves as an Executive in Residence at Canaan Partners, a venture capital firm, where he has been employed since May 2019 and where he focuses on investments in life science companies. Prior to Canaan Partners, Dr. Lonberg served as Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb Co., a biopharmaceutical company, where he led drug discovery efforts for both targeted and immuno-oncology agents, from September 2009 to April 2019. Dr. Lonberg also serves on the boards of directors of various private companies. Dr. Lonberg received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in chemistry from Reed College. He was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and was elected to the National Academy of Engineering in 2015.Our board of directors has determined that Nils Lonberg, Ph.D. will not be nominated to stand for re-election when his current term expires at the Annual Meeting 2026.

Kate Haviland has served as a member of our board of directors since September 2023. Ms. Haviland previously served as the President and Chief Executive Officer and a member of the board of directors of Blueprint Medicines Corporation, or Blueprint, a publicly traded biopharmaceutical company, from April 2022 until its acquisition by Sanofi in July 2025. Ms. Haviland was the Chief Operating Officer at Blueprint from January 2019 to April 2022 and the Chief Business Officer from January 2016 to January 2019. Prior to joining Blueprint, Ms. Haviland served as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Inc. (acquired by Aceragen, Inc.), a biopharmaceutical company, from April 2014 to December 2015, and as head of commercial development at Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a biopharmaceutical and drug development company, from June 2012 to April 2014. Ms. Haviland currently serves on the board of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a biopharmaceutical company, as well as a number of private companies. Ms. Haviland holds a B.A. from Wesleyan University with a double major in Molecular Biology/Biochemistry and Economics and an M.B.A. from Harvard Business School.

Christopher Bowden, M.D. has served as a member of our board of directors since August 2024. From March 2023 until his retirement in November 2025, Dr. Bowden served as the Chief Medical Officer of Remix Therapeutics, Inc., a biotechnology company, or Remix. Dr. Bowden previously served as Strategic Advisor from September 2021 to March 2023 and Chief Medical Officer from May 2014 to September 2021 at Agios Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bowden has also served as a Clinical Consultant for a number of biotechnology and pharmaceutical companies and venture funds, including Rivus Pharmaceutics, Inc. from October 2021 to February 2023, Pyramid Biosciences, Inc. from December 2021 to July 2022, and Remix from March 2022 to March 2023. From October 2019 until March 2023, Dr. Bowden served as a member of the board of directors of Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (formerly Ziopharm Oncology, Inc.), a pharmaceutical company. Dr. Bowden has also served on the boards of directors of various private companies. Dr. Bowden received a B.A. in chemistry from Lake Forest College and an M.D. from Hahnemann University School of Medicine followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board-certified in internal medicine and medical oncology.

Jake Simson, Ph.D. has served as a member of our board of directors since March 2023. Since December 2020, Dr. Simson has served as a Partner of RA Capital Management, L.P., a life sciences investment advisor. Dr. Simson previously served as an associate, analyst and principal at RA Capital Management, L.P. from July 2013 to December 2020. Dr. Simson has served as a member of the board of directors of biotechnology and biopharmaceutical companies Tyra Biosciences, Inc. (Nasdaq: TYRA), Septerna, Inc. (Nasdaq: SEPT), and Janux Therapeutics, Inc. (Nasdaq: JANX) since January 2020, June 2023 and March 2021, respectively. Dr. Simson previously served on the board of directors of DICE Therapeutics, Inc. (Nasdaq: DICE), a biotechnology company, from December 2020 until it was acquired by Eli Lilly and Company in August 2023. Dr. Simson also serves on the boards of directors of various private companies. Dr. Simson received his Ph.D. in Biomedical Engineering from Johns Hopkins University and his B.S. in Materials Science and Engineering from Massachusetts Institute of Technology.

On July 26, 2026, Christy Oliger to serve on the Board as a Class II director, effective as of July 28, 2026. Ms. Oliger is recognized for building industry leading capabilities and teams and was the Senior Vice President, Business Unit Head for Oncology and Genentech from 2017-2020, managing a portfolio of 15 products, contributing U.S. revenue exceeding $13 billion, delivering launches in lung cancer, breast cancer, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), melanoma and leading an organization of more than 800 people. Prior to this role, Ms. Oliger served as Senior Vice President and Business Unit Head, Neurology, Rare Disease, Infectious disease where she was responsible for building the teams and driving successful launches in multiple sclerosis (MS) (Ocrevus), hemophilia (Hemlibra) and spinal muscular atrophy (SMA) (Evrysdi), together the most significant growth drivers in the U.S. business. Prior to these roles, she spent three years as Global Head of Portfolio and Project Management where her team was responsible for the Late-Stage Portfolio Committee comprised of a late-stage development portfolio of greater than 300 projects across multiple therapeutic areas. Christy began her career in life sciences at Schering Plough, a pharmaceutical company. In addition to Bicara, Christy also currently sits on the boards of Vera Therapeutics, Karyopharm Therapeutics, and Replimune Inc. She previously served as a director at Nuvalent Inc. prior to acquisition by GSK, Sierra Oncology prior to acquisition by GSK, Reata Pharmaceuticals prior to acquisition by Biogen, Rayze Bio prior to acquisition by BMS, and Lava Oncology prior to acquisition by Xoma Therapeutics. She holds a B.A. in Economics from University of California, Santa Barbara.

On July 26, 2026, upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed Jeremy Bender, Ph.D. to serve on the Board as a Class I director. Dr. Bender most recently served as Chief Executive Officer, President and a member of the Board of Directors of Day One Biopharmaceuticals, Inc. from September 2020 to April 2026, where he led the company through its evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA for pediatric low-grade glioma and the company's approximately $2.5 billion acquisition by Servier in 2026. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, Inc., a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics, Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc., a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the boards of Mereo BioPharma Group plc and Aura Biosciences, Inc. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an MBA from the MIT Sloan School of Management.

Ivan Hyep has served as our Chief Financial Officer since March 2021 and Treasurer since July 2024. Prior to joining Bicara, Mr. Hyep was the Head of Finance of MOMA Therapeutics, Inc., a biotechnology company, from July 2019 to March 2021. Previously, Mr. Hyep was at Third Rock, a life sciences venture capital firm, as the Director of Finance from January 2018 to March 2021 and Senior Finance Manager from January 2016 to December 2017. Prior to that, Mr. Hyep was Finance Manager at Bain Capital, LP, a private investment firm, from July 2006 to January 2016. Mr. Hyep holds a B.S. in Finance from Bentley University and received his M.B.A. from Boston University.

Lara Meisner, J.D. has served as our Chief Legal Officer since November 2023, Corporate Secretary since December 2023, and Compliance Officer since September 2024. Prior to joining Bicara, Ms. Meisner served as the Chief Legal Officer, Compliance Officer, and Corporate Secretary at Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company, from December 2020 to November 2023. From February 2017 to November 2020, Ms. Meisner held roles of increasing responsibility at Catabasis Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, most recently as the Vice President, Legal and Corporate Secretary. Ms. Meisner received her J.D. from Temple University Beasley School of Law and her B.A. from the University of Michigan.

Carolyn Ng, Ph.D. has served as a member of our board of directors since December 2023. Dr. Ng currently serves as a Business Unit Partner at TPG Life Sciences Innovations, or TPG, a global investment firm, based in San Francisco, where she has led investments into transformative companies in different therapeutic areas since October 2021. Prior to joining TPG, Dr. Ng was a Managing Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she joined in February 2015 and was promoted through various roles to be the co-Head of the investment team from June 2017 to September 2021. Dr. Ng serves on the board of directors of numerous private life sciences companies and previously served on the board of directors of Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company, from June 2017 until June 2020. Dr. Ng also serves as a member of the board of directors of Biocom California, the leading association representing the California life science industry. Dr. Ng holds a Ph.D. in cancer molecular biology from the National University of Singapore, where she was the recipient of the prestigious NGS, Integrative Sciences and Technology, Ph.D. scholarship, and holds a B.S. degree in Pharmacy from the National University of Singapore.